1. Home
  2. PSN vs COGT Comparison

PSN vs COGT Comparison

Compare PSN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

HOLD

Current Price

$45.73

Market Cap

6.3B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$34.58

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSN
COGT
Founded
1944
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.1B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
PSN
COGT
Price
$45.73
$34.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
15
Target Price
$79.18
$36.21
AVG Volume (30 Days)
1.1M
1.8M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
3.77
N/A
EPS
0.49
N/A
Revenue
$6,364,245,000.00
$7,871,000.00
Revenue This Year
$5.87
N/A
Revenue Next Year
$7.61
$1,733.58
P/E Ratio
$94.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.26
$11.61
52 Week High
$89.50
$43.73

Technical Indicators

Market Signals
Indicator
PSN
COGT
Relative Strength Index (RSI) 40.75 37.63
Support Level $45.19 $33.26
Resistance Level $49.61 $37.69
Average True Range (ATR) 1.48 1.32
MACD 0.13 -0.33
Stochastic Oscillator 11.36 13.56

Price Performance

Historical Comparison
PSN
COGT

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: